🚀 Phenaros is growing! 🚀 In the past weeks the team at Phenaros Pharmaceuticals has been growing. We have now extraordinary competence for building and running our Drug Discovery Platform. - Petter Byström joined as BioImage Engineer. He is leading the image and data/AI operations. - Jaime Espinoza, Senior Scientist, is heading our lab operations. - Grecia Garrido, our latest recruitment, is joining as Research Engineer to support our lab and data operations. Welcome all aboard! We are very excited to see our team growing with such talent and taking on projects at full steam!
Om oss
Phenaros is a spin-off drug discovery company from Uppsala University. We use phenomics (large scale cell morphological profiling) combined with automation and governed by AI for the discovery of new and repurposing drugs for rare diseases. Apart from pursuing an in-house drug discovery pipeline, we also establish partnerships where we provide access to our discovery platform. We are an AI-first drug discovery company. This means that AI is central to everything we do, and that wet-lab experiments are carried out to support the models and confirm hypotheses. Human diseases are complex, and AI can accelerate our understanding of complex biology and bridge over to drug discovery. But AI depends fundamentally on access to sufficient but also high-quality data. In Phenaros, we automate the collection of data and treat it as a central asset that we continuously expand, and our AI learns. This leads to faster, safer, and more efficient drug discovery.
- Webbplats
-
www.phenaros.com
Extern länk för Phenaros Pharmaceuticals
- Bransch
- Forskning inom bioteknik
- Företagsstorlek
- 2–10 anställda
- Huvudkontor
- Uppsala
- Typ
- Privatägt företag
- Grundat
- 2022
- Specialistområden
- Drug Discovery , Compound profiling, Morphological profiling, Cell Painting, Phenotypic screening, AI, Automation och Large scale data
Adresser
-
Primär
Få vägbeskrivning
Uppsala, SE
Anställda på Phenaros Pharmaceuticals
-
Ola Spjuth
-
Wing Cheng
Board Member | Director | Senior Advisor | Pricing & Market Access | Life Science Strategy | Angel Investor
-
Jordi Carreras Puigvert
CSO and co-founder at Phenaros Pharmaceuticals | Associate Professor at Uppsala University
-
Jaime Espinoza Ruiz
Senior Scientist at Phenaros Pharmaceuticals
Uppdateringar
-
Last Thursday our CEO Ola Spjuth, CTO Morgan Ekmefjord and BioImage Engineer Petter Byström represented Phenaros Pharmaceuticals at the fantastic Uppsala Innovation Day 2024. Together with other 20 selected exhibiting companies, in a buzzing venue filled with investors and other entrepreneurs, our team engaged in exciting discussions about Phenaros' innovative approach to accelerate drug discovery with AI, Phenomics and Automation. Very exciting times ahead! #phenomics #AIDD #UID2024
-
-
Phenaros Pharmaceuticals omdelade detta
Thank you to everyone who participated in yesterday’s kick-off and investment meeting at Bjerking! 🙌 Special thanks to the BIO-X winners – ArgusEye, Rarity Bioscience , Readily Diagnostics , Phenaros Pharmaceuticals , Strike Pharma AB – and the BIO-X runner ups – Cellda AB, Stardots, Extem Pharma, Oxlantic Medical – who truly impressed us with their pitches. We are excited to follow your journey in the BIO-X Accelerate program and look forward to the progress you’ll make in the Life-Science industry.🚀 We would also like to extend our gratitude to our partner Connect Sverige Region Uppsala for your support!
-
-
Phenaros Pharmaceuticals omdelade detta
Grymt imponerande företag som pitchade på #BioX, STUNS Life science , investerarmöte och imponerande fokus vi har i #Uppsala på utveckling av nya innovationer och bolag. Trevliga lokaler hos värden Bjerking ! Spännande att sedan mingla med entreprenörerna! BIO-X vinnarna – ArgusEye, Rarity Bioscience , Readily Diagnostics , Phenaros Pharmaceuticals , Strike Pharma AB – och BIO-X applikanterna – Cellda AB, Stardots, Extem Pharma och Oxlantic Medical pitchade alla riktigt bra. Ser bra ut för Uppsalas talanger och studenter både idag och i framtiden om dessa företag är tecken i tiden!! Tack till Alla, både företag och arrangörer!! #Studentkonsult #StartUp #Innovation #Tech #LifeScience #Inkubator Uppstuk - IT & Life Science: Konsulter & Karriär
-
-
Phenaros Pharmaceuticals omdelade detta
A new round of BIO-X Accelerate is now commencing. We are pleased to welcome five selected companies: ArgusEye, Phenaros Pharmaceuticals, Rarity Bioscience , Readily Diagnostics, and Strike Pharma AB. Next in line is the company Phenaros Pharmaceuticals. Phenaros Pharmaceuticals use AI and automation to accelerate drug discovery. They employ state-of-the-art AI to guide decisions, along with robotics and automation for intelligent experimentation. As a data-centric company, Phenaros Pharmaceuticals systematically engineers the data used to build their AI system, enabling them to perform the right experiments at the right time, while reducing costs and time in drug discovery cycles. "BIO-X Accelerate offers substantial value for us by providing funding and strategic support to validate and scale our drug discovery platform. This initiative allows us to solidify our technology by partnering with leading pharmaceutical companies and enhances our ability to contribute to bringing effective drugs to market faster." — Jordi Carreras Puigvert, CSO. Are you an investor looking for new and exciting Life Science companies? Sign up for the BIO-X Accelerate Kickoff and Investment Meeting to meet Phenaros Pharmaceuticals and nine other pitching companies. Register here: https://lnkd.in/diurc_gd Funding is available through European Regional Development Fund (ERDF) administered by The Swedish Agency for Economic and Regional Growth (Tillväxtverket).
-
-
We are proud to announce that Phenaros Pharmaceuticals has joined the NVIDIA Inception program! The program will provide us with access to the latest technical resources from NVIDIA, technical expertise, cloud credits, and connections with venture capitalists. We also look forward to take advantage of NVIDIA AI Foundation Models in our emerging drug discovery platform.
-
-
🚀 Fantastic news 🚀 Phenaros Pharmaceuticals is one of the 5 companies awarded the BIO-X Accelerate from STUNS Life science ! We are thrilled and grateful to be part of this exciting program, which will contribute to validating and accelerating our platform. BIO-X Accelerate is a program with the goal of accelerating the development of innovation in the health and/or life science industry. The program uses an industrial approach to support life science-related projects that could fulfil well-defined needs and create IMPACT in healthcare, industry and society. BIO-X Accelerate with the theme IMPACT is a project by STUNS with strategic partners UIC, Connect Uppsala, Create Business Incubator, Lead (Business Incubator), Inkubera and supporting partners Linköping University Innovation, Uppsala University and Örebro University Holding. The project is financed by European Regional Development Fund (ERDF) through The Swedish Agency for Economic and Regional Growth via STUNS program BIO-X Accelerate. We are looking forward to pitch and meet with investors at the kick-off meeting on September 12th! #DataDrivenDrugDiscovery #AIxDrugDiscovery #PhenotypicDrugDiscovery
Are you an investor interested in investing in life science and healthtech? On September 12th we are hosting an investment meeting together with Connect Sverige Region Uppsala in connection to the kickoff of the the BIO-X Accelerate program. Get the chance to meet the selected companies for BIO-X Accelerate and hear bonus pitches from a few selected applicants. 📆 September 12th 🕒 15.00-19.00 📍 Kungsgatan 36A (Bjerking’s office) Register to the event now: https://lnkd.in/dN-7xfqP Read more about the event and companies here: https://lnkd.in/diurc_gd
-
🚀 Exciting News! 🚀 We are thrilled to announce that Phenaros Pharmaceuticals has been accepted into the prestigious UIC - Uppsala Innovation Centre Accelerator program! This opportunity will provide us with invaluable support and resources to drive our mission forward. Being part of the UIC Accelerator means access to a vast network of industry experts, mentors, and strategic partners who will help us accelerate our growth. A huge thank you to the UIC team for believing in our vision. Stay tuned for updates on our journey! #Phenaros #UICAccelerator #Innovation #AIDD #UIC
-
-
Phenaros Pharmaceuticals was at SLAS (Society for Laboratory Automation and Screening) Europe 2024 in Barcelona, what a great event! Jordi Carreras Puigvert presented our work on predicting genotoxicity using Cell Paining and AI, an excellent work between Phenaros and collaborators AstraZeneca.
Great to catchup with my former colleague Jordi Carreras Puigvert, who is sharing his Cell Painting for genotoxicity prediction results at SLAS (Society for Laboratory Automation and Screening) Europe, Barcelona. This work was conducted together with previous colleagues at AstraZeneca Elizabeth Mouchet and Guy Williams. Check out his new company Phenaros Pharmaceuticals which aims to accelerate drug discovery using AI, phenomics and automation!
-
-
A milestone in Phenaros Pharmaceuticals’ journey! As a young, ambitious and most of all forward-thinking company, having the support from our local Uppsala University Innovation office has been fantastic! Thanks for this award!
🎉 Congratulations to Jordi Carreras Puigvert and Ola Spjuth from Uppsala University's Department of Pharmaceutical Biosciences for receiving the Attractive Innovation Project award! 🎈 Jordi and Ola have developed a promising screening method for potential drugs by integrating artificial intelligence with phenomics and automation. This innovative approach aims to provide crucial early-stage insights into the potential of new drug candidates, with the goal of accelerating their identification and advancement. While still in its early stages, their work shows immense promise for saving time and resources in the pharmaceutical industry, and contributing to safer and faster drug development. The team has successfully established Phenaros Pharmaceuticals AB, securing initial investment through Connect Uppsala's network and achieving their first sale. Their dedication to exploring viable routes to market is truly commendable. Today, we celebrated their achievements and recognised their efforts in translating research into meaningful innovations that hold great potential for benefiting society. Well done, Jordi and Ola! 🌟 Make sure to follow Phenaros Pharmaceuticals to stay updated on their exciting journey ahead!
-